XOMA Royalty (XOMA) to Release Earnings on Tuesday

Key Points

• XOMA Royalty is set to release its Q2 2025 earnings on August 12th, with analysts predicting a loss of ($0.12) per share and revenues of $9.39 million.
• In May, XOMA Royalty reported earnings of $0.06 per share, exceeding expectations, and generated revenue of $15.91 million for that quarter.
• XOMA shares fell 1.2% to $26.91, with a market capitalization of $322.03 million and a notable debt-to-equity ratio of 1.18.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect XOMA Royalty to post earnings of ($0.12) per share and revenue of $9.39 million for the quarter.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.32. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. The business had revenue of $15.91 million for the quarter, compared to analyst estimates of $6.75 million. On average, analysts expect XOMA Royalty to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

XOMA Royalty Price Performance

NASDAQ:XOMA traded down $0.39 during midday trading on Friday, hitting $26.03. 18,601 shares of the stock were exchanged, compared to its average volume of 34,667. The company has a market capitalization of $311.50 million, a price-to-earnings ratio of -23.09 and a beta of 1.00. The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 1.18. XOMA Royalty has a one year low of $18.35 and a one year high of $35.00. The business has a 50-day moving average price of $25.86 and a two-hundred day moving average price of $24.23.

Insiders Place Their Bets

In other news, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the stock in a transaction on Friday, May 16th. The stock was sold at an average price of $27.10, for a total value of $10,642,793.30. Following the completion of the sale, the insider owned 1,267,545 shares in the company, valued at $34,350,469.50. This represents a 23.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Owen Hughes sold 25,637 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $25.38, for a total value of $650,667.06. Following the sale, the chief executive officer owned 62,701 shares of the company's stock, valued at $1,591,351.38. The trade was a 29.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 9.10% of the company's stock.

Institutional Trading of XOMA Royalty

A hedge fund recently raised its stake in XOMA Royalty stock. Woodline Partners LP grew its stake in shares of XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) by 7.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 168,550 shares of the biotechnology company's stock after acquiring an additional 12,284 shares during the period. Woodline Partners LP owned 1.41% of XOMA Royalty worth $3,359,000 as of its most recent SEC filing. Institutional investors and hedge funds own 95.92% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Benchmark assumed coverage on XOMA Royalty in a report on Thursday, April 17th. They issued a "buy" rating and a $35.00 price objective for the company. Wall Street Zen downgraded shares of XOMA Royalty from a "buy" rating to a "hold" rating in a report on Sunday, August 3rd. Finally, HC Wainwright restated a "buy" rating and set a $104.00 price objective on shares of XOMA Royalty in a research report on Wednesday, May 28th.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.